文献速递浆细胞疾病

不适合自体干细胞移植的多发性骨髓瘤患者治疗中多克隆免疫球蛋白恢复是更长无进展生存期和总生存期的预后标志

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
PubMed 文献 · Br J Haematol · 2022-04-05

本回顾性研究纳入431例不适合自体干细胞移植的多发性骨髓瘤患者,诊断时81.2%存在免疫麻痹。免疫麻痹与总缓解率、无进展生存期和总生存期呈更差趋势;诊断时有免疫麻痹者中24%在随访期间恢复多克隆免疫球蛋白,恢复者总缓解率、无进展生存期和总生存期均优于未恢复者。

要点

  • 诊断时免疫麻痹见于81.2%的不适合自体干细胞移植的多发性骨髓瘤患者。
  • 诊断时免疫麻痹与总缓解率、无进展生存期和总生存期呈更差趋势,但未达统计学显著。
  • 诊断时有免疫麻痹者中24%在随访期间恢复多克隆免疫球蛋白,恢复者结局更好。

核心结论

  • 不适合自体干细胞移植的多发性骨髓瘤患者在一线治疗中恢复健康的免疫系统与更好的结局相关。

研究设计与样本

  • 回顾性研究评估431例诊断为多发性骨髓瘤且不适合自体干细胞移植的患者中免疫麻痹的影响,中位总生存期为36个月(95%CI:31-40)。

主要发现

  • 诊断时免疫麻痹见于81.2%的患者,与总缓解率呈更差趋势(84.8% vs 74.9%;OR 1.88,95%CI:0.97-3.63)。
  • 诊断时免疫麻痹与更短的无进展生存期相关(22.0 vs 18.2个月;HR 0.775;95%CI:0.590-1.018;p=0.066)。
  • 诊断时免疫麻痹与更短的总生存期相关(45.9 vs 34.2个月;HR 0.746;95%CI:0.551-1.010;p=0.057)。
  • 诊断时有免疫麻痹的患者中24%在随访期间恢复多克隆免疫球蛋白。
  • 恢复多克隆免疫球蛋白者较未恢复者总缓解率更高(96.3% vs 68.2%;OR 12.29,95%CI:3.77-40.06)、无进展生存期更好(HR 0.703;95%CI:0.526-0.941;p=0.018)、总生存期更好(HR 0.678;95%CI:0.503-0.913;p=0.011)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoparesis is the suppression of normal polyclonal immunoglobulins and is present in most patients with newly diagnosed multiple myeloma (MM). The association of immunoparesis at diagnosis, and particularly its recovery along with treatment, with survival in patients ineligible for autologous stem-cell transplantation (ASCT) has not been well established. This retrospective study evaluated the impact of immunoparesis in 431 patients diagnosed with MM, ineligible for ASCT, with a median overall survival of 36 months [95% confidence interval (CI): 31-40]. Immunoparesis was present in 81.2% of patients at diagnosis and was associated with a trend to a worse overall response rate (ORR: 84.8% vs. 74.9%; OR 1.88 (95% CI: 0.97-3.63), shorter progression-free survival (PFS) [22.0 vs. 18.2 months; hazard ratio (HR) 0.775; 95%CI: 0.590-1.018; p = 0.066], and overall survival (OS) (45.9 vs. 34.2 months; HR 0.746; 95% CI: 0.551-1.010; p = 0.057). Twenty-four per cent of patients who had immunoparesis at diagnosis recovered polyclonal immunoglobulins in the follow-up period. Interestingly, these patients had a better ORR (96.3% vs. 68.2%; OR 12.29 (95% CI: 3.77-40.06), PFS (HR 0.703; 95CI%: 0.526-0.941; p = 0.018) and OS (HR 0.678; 95 CI%: 0.503-0.913; p = 0.011) than patients who did not recover it. In summary, restoring a healthy immune system along with first-line treatment in patients with MM, not receiving ASCT, is associated with better outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dávila J, González-Calle V, Escalante F, et al. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival. Br J Haematol. 2022. PMID: 35383901. doi:10.1111/bjh.18182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。